9 February 2016 - Expressing concern over higher generic drug prices, the chair of the House Committee on Oversight and Government Reform and a dozen other Republican committee members recently wrote to the acting FDA commissioner requesting information about the agency’s process for reviewing generic drug applications.

For more details, go to: http://jama.jamanetwork.com/article.aspx?articleID=2488288&utm_source=Silverchair%20Information%20Systems&utm_medium=email&utm_campaign=MASTER%3AJAMALatestIssueTOCNotification02%2F09%2F2016